Impact of the hepatoselective glucokinase activator TTP399 on ketoacidosis during insulin withdrawal in people with type 1 diabetes.

Klara R KleinSchafer C BoederJennifer L R FreemanImogene DunnChris DvergstenSupradeep MadduriErin R GiovannettiCarmen ValcarceJohn B BuseJeremy H Pettus

Published in: Diabetes, obesity & metabolism (2022)

When used as an adjunctive therapy to insulin, TTP399 improves glycaemia without increasing hypoglycaemia in individuals with T1D. During acute insulin withdrawal, TTP399 did not increase BHB concentrations and decreased the incidence of DKA.

Keyphrases

type diabetes
glycemic control
liver failure
risk factors
respiratory failure
drug induced
nuclear factor
immune response
hepatitis b virus
aortic dissection
adipose tissue
toll like receptor
bone marrow
cell therapy
mechanical ventilation